Diagnosis and Staging of Chronic Graft-versus-Host Disease in the Clinical Practice
Diagnosis and Staging of Chronic Graft-versus-Host Disease in the Clinical Practice
复制标题
DOI：
10.1016/j.bbmt.2010.07.017
复制
发表时间：
2011-02-01
影响因子：
4.3
通讯作者：
Wolff, Daniel
中科院分区：
文献类型：
--
作者：
Greinix, Hildegard T.;Loddenkemper, Christoph;Wolff, Daniel
根据专家意见和回顾性数据，美国国立卫生研究院（NIH）共识发展项目提出了用于临床试验的慢性移植物抗宿主病（cGVHD）的总体严重程度和器官严重程度的诊断和分期标准。2008年，德国和奥地利异基因造血干细胞移植（HSCT）中心的代表在德国骨髓和造血干细胞移植工作组（DAG-KBT）年会期间成立了一个cGVHD研究小组，以加强HSCT医生，病理学家，和医疗顾问，重点关注NIH共识标准在临床实践中对患者护理的有用性，并促进HSCT中心之间的合作以及不同的医疗机构之间的合作。参与HSCT的专业。我们首先通过向HSCT中心负责人发送电子问卷，对日常临床常规中cGVHD的诊断、分期和总体分级的现行做法进行了调查。在2009年的3次会议期间，更多的同种异体HSCT中心代表被纳入讨论过程，导致81%的参与者代表了德国、奥地利和瑞士所有同种异体HSCT活动的88%。在2009年11月6日至7日于德国里根斯堡举行的第三次共识会议期间，与会者达成了重要协议，对cGVHD患者的护理产生了强烈影响。分歧的领域，如经典NIH cGVHD和重叠综合征之间的区别，或分配肝脏GVHD 100天后的急性或慢性类别，将进一步评估在参与者中的前瞻性观察性研究在不久的将来。Bioi血液骨髓移植17：167-175（2011）（C）2011美国血液和骨髓移植学会
Based on expert opinion and retrospective data the National Institutes of Health (NIH) Consensus Development Project proposed criteria for diagnosis and staging of both overall severity as well as organ severity of chronic graft-versus-host disease (cGVHD) for use in clinical trials. In 2008, representatives of German and Austrian allogeneic hematopoietic stem cell transplant (HSCT) centers established a study group on cGVHD during the annual meeting of the German Working Group on Bone Marrow and Blood Stem Cell Transplantation (DAG-KBT) to intensify a dialog among HSCT physicians, pathologists, and medical consultants focusing on the usefulness of the NIH consensus criteria for patient care in clinical practice and to promote collaborations between HSCT centers as well as different medical specialities involved in HSCT. We first conducted a survey of current practices of diagnosis, staging, and overall grading of cGVHD in daily clinical routine by sending an electronic questionnaire to the heads of the HSCT centers. During 3 meetings in 2009, more representatives of allogeneic HSCT centers were included into the discussion process, resulting in 81% participation representing 88% of all allogeneic HSCT activities in Germany, Austria, and Switzerland. During the third consensus meeting held in Regensburg, Germany, from November 6 to November 7, 2009, important agreements were achieved among participant having a strong impact on care of patients with cGVHD. Areas of disagreement such as distinction between classical NIH cGVHD and overlap syndrome or assignment of liver GVHD after day 100 to acute or chronic category will be further assessed in prospective observational studies among participants in the near future. Bioi Blood Marrow Transplant 17: 167-175 (2011) (C) 2011 American Society for Blood and Marrow Transplantation